Abstract 5734
Background
Despite high sensitivity to first-line chemotherapy (CT), most small-cell lung cancer (SCLC) patients relapse. Efficacy of 2nd-line CT is modest and influenced by treatment-free-interval (TFI). Topotecan demonstrated modest activity and significant haematological toxicity. Paclitaxel-based regimens showed to be active in this setting. Nab-paclitaxel, compared to paclitaxel, has a reduced incidence of hypersensitivity reactions and of neutropenia. Safety and efficacy in relapsed SCLC have not been prospectively studied.
Methods
This open-label phase II study enrolled patients with extensive- (ED) or limited-disease (LD) SCLC progressed during or after etoposide/platinum-based 1st-line CT with the aim to assess the activity and safety of Nab-paclitaxel. Patients were classified as refractory (TFI < 60 days) or sensitive (TFI ≥ 60 days). Eligible patients received Nab-paclitaxel 100 mg/mq on days 1,8,15 every 28 days for 6 cycles, progressive disease or intolerable toxicity. Computed tomography scan was performed every 2 cycles. Treatment could be continued beyond the 6th cycle in presence of prolonged response, clinical benefit and good tolerance to drug. The primary endpoint was objective response, evaluated according to RECIST v1.1 criteria. The secondary endpoints were toxicity, measured according to NCI-CTCAE v4.03, progression-free and overall survival.
Results
From January 2017 to March 2018, 68 patients (25 refractory and 43 sensitive) were enrolled in the modified intentiontotreat population. Median age was 68.5 years (range 44-80). 44 patients were males and 57 had ED. Median follow-up was 5.8 months (IQR 3.37.1). Objective responses are currently being reviewed by an independent radiology panel. Most common toxicities (of all grades) were anemia (39%), leukopenia (27%), neutropenia (28%), nausea (19%), diarrhoea (21%), fatigue (52%), peripheral neuropathy (19%). The only severe toxicity (grade ≥3) was neutropenia (9%). In 13 patients treatment is still ongoing while 3/55 (5%) patients discontinued treatment for toxicity.
Conclusions
This is the first prospective study of Nab-paclitaxel for relapsed SCLC. Nab-paclitaxel demonstrated a manageable toxicity profile. Final activity data will be available for the meeting.
Clinical trial identification
EudraCT: 2016-000408-27; NCT03219762.
Legal entity responsible for the study
GOIRC (Gruppo Oncologico Italiano di Ricerca Clinica).
Funding
Celgene.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3816 - A prediction panel with DNA methylation biomarkers for lung adenocarcinoma
Presenter: Nan Shen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5242 - Novel genomic classifier for early stage colorectal cancer patients
Presenter: Elisabeth Letellier
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5404 - Baseline Blood Immune Profiling to Predict Response to antiPD-1 in Patients with Advanced Non-Small Cell Lung Cancer
Presenter: Emanuela Romano
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5462 - Evaluation of clinicopathological and molecular criterias for screening of exonucleasic domain POLE (edPOLE) mutated patients in proficient Mismatch Repair (pMMR) colorectal and endometrial cancers.
Presenter: Justine Cohen
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5465 - Immune prognostic index (IPI) and Hyper-Progressive disease (HPD) in patients (pts) exposed to targeted agents (TAs) in Phase 1 trials (Ph1T): can lessons from immune checkpoint inhibitors (ICIs) be translated to other scenarios?
Presenter: Ignacio Matos Garcia
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5742 - Combination of baseline LDH, performance status and age to identify solid tumor patients with higher probability of response to anti-PD1 and PDL1 monoclonal antibodies
Presenter: Maria Silvia Cona
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5790 - Effects of concomitant genetic alterations on cancer patient overall survival
Presenter: Yu Wang
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5144 - Circulating Exosomal Integrin _v_5 Predicts Liver Metastasis and Prognosis in Human Colorectal Cancer
Presenter: Dake Chu
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5149 - Circulating and tumor-associated caspase-4: a novel diagnostic and prognostic biomarker for Non-Small Cell Lung Cancer patients?
Presenter: Rosalinda Sorrentino
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract
5673 - Smokers and COPD patients have high circulating caspase-4 levels: is it an alarm?
Presenter: Michela Terlizzi
Session: Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research
Resources:
Abstract